

TEN YEARS EXPERIENCE WITH JORGE LOBO'S DISEASE IN THE STATE OF ACRE, AMAZON REGION, BRAZIL

William John WOODS(1), Andréa de Faria Fernandes BELONE(2), Léia Borges CARNEIRO(1) & Patrícia Sammarco ROSA(2)

SUMMARY

Jorge Lobo's disease is a cutaneous and subcutaneous mycosis that affects patients in the Amazon region. The number of patients is relatively small, but the real situation of the disease as public health problem is not known, because Jorge Lobo's disease is not a notifiable disease. This study aims to report the clinical evolution in patients affected and to determine the prevalence and areas of occurrence of the disease. A retrospective study was carried out based on the analysis of the clinical records, which included a collection of photographs of patients in the Department of Sanitary Dermatology, in Rio Branco, and patients seen in the interior of the state. In a decade, in Rio Branco, 249 cases of the disease were reported, 30 were females and 219 males. Of these patients, 153 had localized lesions, 94 of them were on one ear, 55 had multifocal lesions and 41 had disseminated lesions. The average time between the onset of symptoms and diagnosis was 19 years. The average age at the time of diagnosis was 53 years, and ages ranged from 14 to 96 years.

KEYWORDS: Jorge Lobo's disease; Epidemiology; Prevalence; *Lacazia loboi*.

INTRODUCTION

Jorge Lobo's disease, also known as lobomycosis and lacaziosis, was described for the first time in 1931 by Jorge Oliveira Lobo, physician and professor of Dermatology from the School of Medicine of Recife, PE¹³. The patient, a 52 years-old male, had worked as a rubber cutter in the Amazon and had skin lesions resembling keloid scars. Between 1938 and 1962 there were 29 cases registered in Brazil, one in Costa Rica, two in Venezuela, and two in French Guiana¹¹. BARUZZI *et al.*^{2,4} reported numerous cases among Caiabi Indians living in an area between the rivers Teles Pires and Tapajós, in the North of the state of Mato Grosso. Interestingly, when these Indians were transferred to the Xingu Indigenous National Park, no new case arose in the tribe. This may indicate there was no source of contamination in the Xingu National Park. Other indigenous tribes that inhabit the North of Mato Grosso State, in Brazil, do not have the disease. The high incidence among Caiabi Indians indicates that besides the risk factors, it is likely that there is a genetic susceptibility that predisposes to Jorge Lobo's disease.

In Europe, one case was observed by SYMMERS³¹, the patient was an attendant who took care of a dolphin infected with the disease. BURNS *et al.*⁵ reported the first case in the United States in a man of 42 years from Georgia, which referred to the appearance of lesions on the skin, after a trip to Venezuela where he had done rappelling in Angel Falls in Canaima.

Some authors refer to constant increase in number of Jorge Lobo's disease cases. SILVA & NEVES²⁸ cited 252 cases in Brazil and 385 in the world. According to PRADINAUD & TALHARI²¹, the statistics in 1996 was 418 cases worldwide. This remained unchanged until 1998, when the number of cases reported in Brazil was 255⁷. OPROMOLLA *et al.*¹⁷ estimated that 458 patients were diagnosed with the disease, of which 295 were in Brazil and 40 of these cases were in the state of Acre.

Jorge Lobo's disease is found, almost exclusively, in the tropical zone of the rainforest. The Brazilian Amazon valley has the climatic characteristics favoring the disease, tropical, hot and humid equatorial climate (Fig. 1). Until today, it is unclear which factors may act in the susceptibility and spread of the disease². The transmission of Jorge Lobo's disease is probably by contact of the infectious material with skin solutions of continuity. Evidence suggests the skin as portal of entry of the fungus by the fact that the lesions are located almost exclusively in skin tissue.

The proven presence of dolphins with *L. loboi* indicates that the infective material must be present in seawater or freshwater. In 1971, MIGAKI *et al.*¹⁵ described the first case of the disease in dolphins, a specimen (*Tursiops truncatus*) caught on the West coast of Florida. A second case, also in Florida, was studied by WOODWARD³⁵. DE VRIES & LAARMAN⁸ described a new case in a dolphin (*Sotalia guianensis*) caught in the estuary of the river Surinam. In 1970, another dolphin was

(1) Departamento de Dermatologia Sanitária, Avenida Nações Unidas 700, Bosque, 60908-620 Rio Branco, Acre, Brasil.

(2) Instituto Lauro de Souza Lima, Rodovia Cmtc J.R. Barros, Km 225, 17034-971 Bauru, SP, Brasil.

Correspondence to: Patrícia Sammarco Rosa, Instituto Lauro de Souza Lima, Rodovia Cmtc J.R. Barros, Km 225, 17034-971 Bauru, SP, Brasil. Phone: +55.14.31035911, Fax: +55.14.31035914. E-mail: prosa@ils.br

Table 1
Therapeutic results in Jorge Lobo's disease

AUTHOR	DRUGS USED	RESULTS
REYES <i>et al.</i> 1960 ²²	Sulfadimetoxine 1000 mg/day	Improvement of the infiltrations
SILVERIE <i>et al.</i> , 1963 ²⁹	Sulfametoxipiridazine 500 mg/day	Reduction of the nodules
LONDOÑO, 1968 ¹⁴	Anfotericin B infiltration	Unsatisfactory
BARUZZI & AZEVEDO, 1991 ¹	Clofazimine, 2 years 100 a 200 mg/day	Unsatisfactory
SILVA, 1978 ²⁶	Clofazimine 3 to 6 months 200 mg/day	Slight reduction of lesions
TALHARI <i>et al.</i> , 1981 ³²	Clofazimine 6 months to 3 years 200 mg/day & electrocoagulation	Decreased number of fungi Some regression of lesions
CUCÊ <i>et al.</i> , 1980 ⁶	Ketaconazole 90 days 400 mg/day	Decreased number of fungi Some regression of lesions
BARUZZI <i>et al.</i> , 1980 ³	Ketaconazole 400 mg/day	Moderate improvement
LAWRENCE & AJELLO, 1986 ¹²	Ketaconazole 6 months 200 mg/day	Unsatisfactory
OPROMOLLA, 1996 ¹⁶	Itraconazole 6 months 100 to 200 mg/day	Unsatisfactory
PRADINAUD & TALHARI, 1996 ²¹	Fluorocitosine, 50 days 100 mg/kg	Unsatisfactory
OPROMOLLA, 2000 ¹⁸	Anfotericin B, DDS, Fluorocitosine Terbinafine and Clofazimine	Softening of the lesions
OPROMOLLA 2000 ¹⁸	Clofazimine, DDS, Fluorocitosine and Itraconazole	Decreased viability
FISCHER <i>et al.</i> , 2002 ¹⁰	Itraconazole and Clofazimine 100 mg/kg	Clinical cure
ROSA <i>et al.</i> 2009 ²⁴	Itraconazole, Clofazimine, DDS Surgical excision	Clinical cure

DDS = dapsona.

lip. Since these four patients all lived in interior of the forest, there is no recorded evidence of transmission from one person to another, it is most likely that they became contaminated individually from an environmental source of the fungi.

LACAZ *et al.*¹¹ indicate that no particular ethnic group has a greater susceptibility to acquire *L. loboi* and described the disease in white, blacks and Indians. However, the results of the present study show that there are very few Caucasians presenting Jorge Lobo's disease in the state of the Acre, however, this could be a bias, because most of the population in Acre, with or without the disease, has dark skin.

LACAZ *et al.*¹¹ also reported that the disease affects mainly rubber cutters, miners, i. e., people who are in direct contact with the tropical forest. Similarly, all the patients in the present study worked or lived in the interior of the rain forest or on the banks of the rivers when the first symptoms appeared. Table 2 shows the distribution according to the municipality where the patients first appeared with symptoms of Jorge Lobo's disease. There were no patients coming from the municipalities

of Bujari, Assis Brasil, Jordão or Rodrigues Alves showing symptoms of the disease. Patients of the municipalities of Sena Madureira, Rio Branco, Xapuri, Plácido de Castro, Porto Acre and Epitaciolândia (municipalities with the highest numbers of cases), have easy access to the clinical center of the Dermatology Department in Rio Branco. Most of the other patients were seen when the medical doctor in the present work and his team traveled within these municipalities working with the Program for Elimination of Leprosy. We observed that among all patients who acquired the disease in the municipality of Sena Madureira, 14 of them lived on the banks of the Antimari River at the time, which is an endemic area for Jorge Lobo's disease. Fig. 1 shows the distribution of Jorge Lobo's Disease in the municipalities of the Acre, a state with a population of 691,169 inhabitants, with 4.5 inhabitants/km²-population density and altitude of 153 m above sea level in the capital, Rio Branco.

The river Purus and its tributaries pass through the municipalities of Sena Madureira, Manoel Urbano, Santa Rosa, Rio Branco, Xapuri, Brasiléia, Epitaciolândia and Boca do Acre in the state of Amazonas. Among the eight patients in the state of Amazonas, six are from Boca do

Table 2

Distribution of Jorge Lobo's disease cases diagnosed in the State of Acre between 1998 and 2008, divided by municipality where patients lived when the first symptoms of the disease appeared

Municipality	Number of cases
Sena Madureira	83
Rio Branco	33
Xapuri	28
Plácido de Castro	16
Porto Acre	15
Epitaciolândia	12
Tarauacá	11
Manoel Urbano	7
Cruzeiro do Sul	6
Senador Guiomar	5
Acrelândia	5
Brasileia	4
Capixaba	4
Mancio Lima	3
Porto Walter	2
Feijó	2
Santa Rosa	2
Marechal Taumaturgo	1
Amazonas State *	8
Rondonia State *	2
Total	249

* Treated in the Department of Dermatology in Rio Branco.

Acre. This indicates that the Purus River and its tributaries, which include the river Antimari, are the largest endemic areas of Jorge Lobo's disease in Acre. We believe that the valley of the river Juruá, a region that was not thoroughly studied, must have a hidden prevalence of the disease.

Clinical aspects: Among the 249 patients in this study, 153 had localized lesions, 94 of them had lesions in one ear, of these 38 had lesions in the right ear and 56 in the left ear. None of the patients had lesions in both ears, but three patients had lesions in one ear and in another region of the body. This suggests multiple inoculation sites, as previously stated by OPROMOLLA *et al.*²⁰. From the total number of cases, 55 had multifocal lesions and 41 had disseminated lesions (Fig. 2a, b, c, d).

Lesions were observed in the right upper limb in 34 patients and in the left in 36 patients. Seven patients had lesions on both upper limbs. In the lower limb, 20 patients had lesions on the right member and 34 on the left, four patients had lesions on both lower limbs and eight patients had lesions on the face. Another eight patients had lesions on the abdomen and six on the back. Two patients had lesions on the buttocks and one on the right (female) breast.



Fig. 2 - Characteristic clinical forms of Jorge Lobo's disease. A. Isolated form; B. Multifocal form on lower limb; C. Extensive disseminated form; D. Ulcerated form on leg and foot.

We draw attention to the fact that the left side of the body is the most affected. A possible explanation for this is that rubber cutters going through the forest carry the cutlass in his right hand and use their left hand or foot to push clear the bushes they have cut, making the left side more vulnerable to trauma through where fungi probably penetrate the skin.

Lesions may appear at any anatomic site, but there are no reports of lesions affecting the mucous membranes. Despite two patients with ulcerated lesions developing squamous cell carcinoma, the general health of the patient is good. The local symptom is intensive itching. When there are extensive lesions disseminated over a large area, beside the deformity they cause, the itching becomes unbearable. Ulceration is usually secondary to trauma because of itching.

Treatment of Jorge Lobo's disease in Acre: Because of the lack of an effective medical treatment, in Acre, since 1979, patients have been submitted to surgeries to remove lesions, which improved substantially their quality of life. However, many of them presented recurrence of the symptoms after variable periods post surgery.

Over thirty years of experience working in the Leprosy Elimination Program of Acre, also following the guidelines of the distinguished Dr. Diltor OPROMOLLA¹⁸ (dapsone and clofazimine) and of the esteemed professor of Dermatology, Sinésio TALHARI *et al.*³² (clofazimine 200 mg/6 months), the authors of the present work have used various forms of treatment for Jorge Lobo's disease, all of them without very promising results¹⁷.

From the total number of patients in Acre, 10 patients who had also been treated for leprosy demonstrated the best results of treatment. One of these patients, a female patient from the interior of the state finished her treatment for multibacillary leprosy, (rifampicin, clofazimine and dapsone), begged not to suspend the treatment because the Jorge Lobo's disease lesions were softening and the itching was decreasing. During follow-up of the leprosy patients treated for multibacillary leprosy, who also had Jorge Lobo's disease, we observed diminished itching caused by Jorge Lobo's disease; the lesion showed mild atrophy and when the lesion was surgically removed, there was no recurrence. These patients were periodically examined, considering the clinical evolution and laboratorial

examinations (biopsy and viability determination of the fungi collected from skin lesions) to document the improvement.

CONCLUSION

The prevalence of Jorge Lobo's disease in the state of Acre is not very high, 3.05/10,000 inhabitants, but the deformity and decreased productivity at work create a social burden for the carriers of this disease. We call attention to the fact that 96% of the patients are in the macro region of the valleys of the rivers Purus and Acre, where it is relatively easy to access the clinic of the Department of Sanitary Dermatology in Rio Branco. In the macro region of the river Juruá there is no health service available and there must be a hidden prevalence in this area. Nobody knows the true prevalence of this disease, which does not require compulsory notification.

It was an interesting coincidence to find patients who have Jorge Lobo's disease and are treated for multibacillary leprosy who showed great improvement of the lesions of Jorge Lobo's disease, some no longer with viable fungi. Perhaps this treatment could be the starting point for further search for a cure for Jorge Lobo's disease.

RESUMO

Dez anos de experiência com a Doença de Jorge Lobo no estado do Acre, região amazônica, Brasil

A doença de Jorge Lobo é micose cutânea e subcutânea que afeta pessoas na região Amazônica. O número de pacientes é relativamente pequeno, no entanto, a real prevalência da doença como problema de saúde pública é pouco conhecida. A doença de Jorge Lobo não é de notificação compulsória. Este estudo teve como objetivo determinar a prevalência, as áreas de ocorrência da doença de Jorge Lobo, além de sua evolução clínica. Um estudo retrospectivo foi desenvolvido com base na análise de prontuários de pacientes, incluindo documentação fotográfica dos mesmos, que foram atendidos no Departamento de Dermatologia Sanitária em Rio Branco e no interior do Estado. Foram registrados 249 casos em uma década em Rio Branco, 30 mulheres e 219 homens. Do total 153 apresentavam lesões localizadas, 94 lesões em apenas uma orelha, 55 lesões multifocais e 41 lesões disseminadas. A média de tempo entre o início dos sintomas e o diagnóstico foi de 19 anos. A média de idade no momento do diagnóstico foi de 53 anos, e as idades variaram de 14 a 96 anos.

ACKNOWLEDGEMENTS

The author would like to thank the Health professionals at Departamento de Dermatologia Sanitária in Rio Branco, Acre, for their help in assistance to the patients and the LACEN Laboratory of Rio Branco, Acre, for providing resources for sample processing and viability determination of *Lacazia loboi*.

AUTHORS CONTRIBUTIONS

WJW, AFFB and PSR contributed to the study concept and drafting of the manuscript. WJW and LBC were responsible for patients' management. AFFB and PSR were responsible for the complementary exams, histopathology and viability determination. All authors undertook

the medical literature search, read and approved the final manuscript.

REFERENCES

1. Baruzzi RG, Azevedo RA. Doença de Jorge Lobo. In: Meira DA. Clínica de doenças tropicais e infecciosas. Rio de Janeiro: Interlivros; 1991. p. 299-306.
2. Baruzzi RG, Lacaz CS, De Souza FA. A história natural da doença de Jorge Lobo. Ocorrência entre índios Caiabi (Brasil Central). *Rev Inst. Med Trop Sao Paulo*. 1979;21:303-38.
3. Baruzzi RG, Marcopito LF, Pascalicchio FV. Emprego do ketoconazole no tratamento da doença de Jorge Lobo. In: 16º Congresso da Sociedade Brasileira de Medicina Tropical; 1980; Natal, RN. Resumos. nº 350.
4. Baruzzi RG, Castro RM, D'Andretta Jr C, Carvalho S, Ramos OL, Ponrtes PL. Occurrence of Lobo's blastomycosis among "Caiabi" Brazilian Indians. *Int J Dermatol*. 1973;12:95-9.
5. Burns RA, Roy JS, Woods C, Padhye AA, Warnock D. Report of the first human case of lobomycosis in the United States. *J Clin Microbiol*. 2000;38:1283-5.
6. Cucê LC, Wroclawski EL, Sampaio SAP. Treatment of paracoccidioidomycosis, candidiasis, chromomycosis, lobomycosis and mycetoma with ketoconazole. *Int J Dermatol*. 1980;19:405-8.
7. De Brito AC, Quesada JAS. Lacaziose: revisão e atualização. *An Bras Dermatol*. 2007;82:461-71.
8. De Vries GA, Laarman JJ. A case of Lobo's disease in the dolphin *Sotalia guianensis*. *J Aquat Mammals*. 1973;1:26-33.
9. Dias LB, Sampaio MM, Silva D. Jorge Lobo's disease. Observations on its epidemiology and some unusual morphological forms of the fungus. *Rev Inst Med Trop Sao Paulo*. 1970;12:8-15.
10. Fischer M, Chrusciak-Talhari A, Reinel D, Talhari S. Successful treatment with clofazimine and itraconazole in a 4 year-old patient after 32 years duration of disease. *Hautarzt*. 2002;53:677-81.
11. Lacaz CS, Baruzzi RG, Rosa, MCB. Doença de Jorge Lobo. São Paulo: Editora da USP/IPSIS; 1986.
12. Lawrence DN, Ajello L. Lobomycosis in Western Brazil: report of a clinical trial with ketoconazole. *Am J Trop Med Hyg*. 1986;35:162-66.
13. Lobo J. Um caso de blastomicose, produzido por uma espécie nova, encontrado em Recife. *Rev Méd Pernambuco*. 1931;1:763-75.
14. Londoño F. Blastomicose queloidiana. A propósito de um caso tratado com anfotericina B. *Med Cutânea*. 1968;2:521-4.
15. Migaki G, Valério VA, Irvine B, Garner MR. Lobo's disease in an Atlantic bottle-nosed dolphin. *J Am Vet Med Assoc*. 1971;159:578-82.
16. Opromolla DVA. Experimentação terapêutica com o itraconazol na lobomicose. In: 51º Congresso Brasileiro de Dermatologia; 1996; Recife, PE. Resumos.
17. Opromolla DVA, Tabora PRO, Tabora VBA, Viana S, Furtado JF. Lobomicose: relato de 40 casos novos. *An. Bras Dermatol*. 1999;74:135-41.
18. Opromolla DVA. Estudos terapêuticos na doença de Jorge Lobo. In: 55º Congresso Brasileiro de Dermatologia; 2000; Salvador, BA. Resumos.
19. Opromolla DVA, Belone AFF, Tabora PRO, Tabora VBA. Correlação clínico-patológica em 40 casos novos de lobomicose. *An. Bras. Dermatol.*, 2000;75:425-34.
20. Opromolla DVA, Belone AFF, Tabora PR, Rosa PS. Lymph node involvement in Jorge Lobo's disease: report of two cases. *Int J Dermatol*. 2003;42:938-41.

21. Pradinaud R, Talhari S. Lobomycose. In: Encyclopedie Medico Chirurgicale, Maladies Infectieuses. Paris: Elsevier; 1996. 8-608-A-10:1-6.
22. Reyes O, Gohman M, Goldstein C. Blastomycosis queloidiana o enfermedad de Jorge Lobo. *Dermatol Venez.* 1960;2:245-55.
23. Rodriguez-Toro G. Lobomycosis. *Int J Dermatol.* 1993;32:324-32.
24. Rosa PS, Soares CT, Belone AFF, Vilela R, Ura S, Cury-Filho M, *et al.* Accidental Jorge Lobo's disease in a worker dealing with *Lacazia loboi* infected mice: a case report. *J Med Case Reports.* 2009;3:1-5.
25. Silva D. Micose de Lobo. *Rev Soc Bras Med Trop.* 1972;6:85-98.
26. Silva, D. Traitement de la maladie de Jorge Lobo par la clofazimine (B663). *Bull Soc Path Exot.*, 1978;71:409-12.
27. Silva D, De Brito A. Formas clínicas não usuais de micose de Lobo. *An Bras Dermatol.* 1994;69:133-6.
28. Silva D, Neves C. Dois casos novos de micose de Lobo: atualização estatística. *An Bras Dermatol.* 1995;70:127-9.
29. Silverie R, Ravisse P, Vilar JP, Moulins C. La blastomycose chéloidienne ou maladie de Jorge Lobo en Guyane Française. *Bull Soc Path Exot.* 1963;56:29-35.
30. Sotos J. Golfinho fêmea morre de doença rara. Available from: <http://www.golfinhos.net/en/portal/noticias/202>. Accessed: November 4, 2007
31. Symmers WC. A possible case of Lobo's disease acquired in Europe from a bottle-nosed dolphin (*Tursiops truncatus*). *Bull Soc Path Exot.* 1983;76:777-84.
32. Talhari S, Cunha MGS, Barros MLB, Gadelha AR. Doença de Jorge Lobo. Estudo de 22 casos novos. *Med Cutan Ibero Lat Am.* 1981;9:87-96.
33. Van Bressem MF, Santos MC, Oshima JE. Skin diseases in Guiana dolphins (*Sotalia guianensis*) from the Paranaguá estuary, Brazil: a possible indicator of a compromised marine environment. *Mar Environ Res.* 2009;67(2):63-8.
34. Woods WJ, Belone AFF, Rosa PS, Ura S. Lobomycose, tratamento com poliquimioterapia multibacilar (PQT/MB). In: Simpósio Nacional de Micologia Médica: Cromoblastomycose, Lobomycose, Paracoccidioidomycose e Criptococose; 2005; Belém, PA. Anais.
35. Woodard JC. Electron microscopic study of lobomycosis (*Loboa loboi*). *Lab Invest.* 1972;27:606-12.

Received: 24 July 2009

Accepted: 8 July 2010